TLPP.F Panoramica delle azioni Telix Pharmaceuticals Limited, una società biofarmaceutica in fase commerciale, si concentra sullo sviluppo e la commercializzazione di radiofarmaci terapeutici e diagnostici per il cancro e le malattie rare in Australia, Belgio, Giappone, Svizzera e Stati Uniti. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Telix Pharmaceuticals Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Telix Pharmaceuticals Prezzi storici delle azioni Prezzo attuale dell'azione AU$14.28 Massimo di 52 settimane AU$16.74 Minimo di 52 settimane AU$6.16 Beta 2.41 Variazione di 1 mese -10.44% Variazione a 3 mesi -1.37% Variazione di 1 anno 123.07% Variazione a 3 anni 128.79% Variazione a 5 anni 1,299.66% Variazione dall'IPO 1,209.77%
Notizie e aggiornamenti recenti
Telix Pharmaceuticals Limited Submits its Biologics License Application to the United States Food and Drug Administration for TLX250-CDx (Zircaix, Zr- girentuximab) Kidney Cancer Imaging Jan 01
Telix Pharmaceuticals Limited Completes the Installation of Two New Cyclotron at Telix Manufacturing Solutions in Brussels South, Belgium Dec 19
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent Oct 24 Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy Oct 08 Vedi altri aggiornamenti
Telix Pharmaceuticals Limited Submits its Biologics License Application to the United States Food and Drug Administration for TLX250-CDx (Zircaix, Zr- girentuximab) Kidney Cancer Imaging Jan 01
Telix Pharmaceuticals Limited Completes the Installation of Two New Cyclotron at Telix Manufacturing Solutions in Brussels South, Belgium Dec 19
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent Oct 24 Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy Oct 08 Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy
Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma Oct 03
Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million. Sep 23
Telix Submits NDA for TLX101-Cdx (Pixclara®) Brain Cancer Imaging Agent Aug 28
Telix Pharmaceuticals Limited Announces Expanded Access Program Opens in the U.S. for Tlx101-Cdx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent Jul 30 Telix Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024 Telix Pharmaceuticals Limited has withdrawn its Follow-on Equity Offering in the amount of $201.79 million. Jun 15
Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent May 28
Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million. May 19 Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million. May 18
Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024 Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of ARTMS, INC.
Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million. Apr 11
Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million. Apr 09
Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent Mar 26 Telix Pharmaceuticals Limited (ASX:TLX) signed an agreement to acquire ARTMS, INC. for approximately $84 million. Mar 05
Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million. Feb 27 Telix Pharmaceuticals Limited Provides Earnings Guidance for Full Year Revenue 2024
Telix Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 22, 2024 Jan 08
Telix Pharmaceuticals Limited Announces Executive Changes Dec 20
Telix Pharmaceuticals Limited Submits Biologics License Application for TLX250-CDx (Zircaix) for Imaging of Kidney Cancer Dec 19
Telix Pharmaceuticals Limited Announces First Patient Dosed in European Named Patient ( Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent Dec 04
Telix Pharmaceuticals Limited Announces Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS Nov 30
Telix Pharmaceuticals Limited (ASX:TLX) signed a non-binding term sheet to acquire QSAM Biosciences, Inc. (OTCPK:QSAM) for $33.1 million. Nov 15
Telix Pharmaceuticals Limited (ASX:TLX) acquired Lightpoint Surgical Limited from Lightpoint Medical, Ltd AUD 51 million. Nov 02 Telix Pharmaceuticals Limited Announces Positive Preliminary Results from the Phase I ProstACT SELECT Study of Its rADC Therapy Candidate TLX591 Oct 19
Telix Pharmaceuticals Limited Announces First Patients Dosed in Chinese Imaging Studies Oct 18
Telix Pharmaceuticals Limited to Report Q3, 2023 Results on Oct 18, 2023 Oct 11
Telix Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 23, 2023 Aug 15
Telix Pharmaceuticals Limited to Report Q2, 2023 Results on Jul 19, 2023 Jul 13
Telix Pharmaceuticals Limited to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI Jun 24
Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire Lightpoint Surgical Limited from Lightpoint Medical, Ltd for AUD 51 million. Jun 22
Telix Pharmaceuticals Limited Announces First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion Jun 19
Telix Pharmaceuticals Limited Announces Detailed Positive Results from its Completed Pivotal Phase III ZIRCON Trial Feb 20
Telix Pharmaceuticals Limited to Report Q4, 2022 Results on Jan 18, 2023 Jan 12
Telix Pharmaceuticals Limited Announces ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances Dec 22
Telix Pharmaceuticals Limited Announces Leadership Changes Dec 05
Telix Pharmaceuticals Limited Announces Illuccix Kit for the Preparation of Gallium Ga 68 Gozetotide Injection Nov 23
Telix Pharmaceuticals Limited Announces That First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy Nov 22
Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire Optimal Tracers from Northern California PET Imaging Center. Nov 15
Telix Pharmaceuticals Limited Announces Positive Topline Results from Overseas Phase III Clinical Trial Has Met Clinical Endpoints Nov 11
Telix Pharmaceuticals Limited Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study Nov 07
Telix Pharmaceuticals Limited Presents Preliminary Data on TLX250-CDx Indication Expansion at EANM Oct 18 Telix Pharmaceuticals Limited to Report Q3, 2022 Results on Oct 20, 2022 Telix Pharmaceuticals Limited Announces Health Canada Approves Illuccix for Prostate Cancer Imaging Oct 14
Telix Pharmaceuticals Limited Announces First Patient in New Zealand Dosed with Illuccix Sep 30 Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate
Telix Pharmaceuticals Limited and GenesisCare announce First Patient Enroll in ProstACT TARGET Study Sep 27
Telix Pharmaceuticals Limited Reports the Final Results from the IPAX-1 Ph I/II Study of TLX101 Therapy Iodo-Phenylalanine Sep 21
Telix Pharmaceuticals Limited and Atonco S.A.S. Announce That the Final Patient Dosed in A Phase I Study of TLX250-CDx in Patients with Non-Muscle Invasive Bladder Cancer Aug 24
Telix Pharmaceuticals Limited to Report First Half, 2022 Results on Aug 18, 2022 Aug 05
Telix Pharmaceuticals Limited Reports on APAC Regulatory Progress Prostate and Kidney Cancer Imaging Aug 02 Telix Pharmaceuticals Limited Appoints Kevin Richardson as CEO, Telix Americas Telix Pharmaceuticals Limited Announces Management Change
Telix Pharmaceuticals Limited Provides Reimbursement and Launch Updates May 30
Telix Pharmaceuticals Limited Announces First Patient Has Been Dosed in the 'STARLITE 2' Phase II Study of the Company's Investigational Renal Cancer Therapy, TLX250 (177Lu-DOTA-girentuximab), At Memorial Sloan Kettering Cancer Center (MSK) in New York May 05
Telix Pharmaceuticals Limited Announces First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent Apr 16
Telix Pharmaceuticals Limited Announces ProstACT TARGET Phase II Clinical Trial Update Apr 12
Telix Pharmaceuticals Limited Announces Commercial Launch of Illuccix in the United States Apr 04
Telix Pharmaceuticals Limited Announces Board Changes Mar 31 Telix Pharmaceuticals Limited Completes ZIRCON Phase 3 Imaging Study Targets Enrolment Mar 10
Telix Pharmaceuticals Limited, Annual General Meeting, May 18, 2022 Feb 25
Telix Pharmaceuticals Limited Appoints Darren Smith as Deputy Group Chief Financial Officer Feb 04
Telix Pharmaceuticals Limited to Report Fiscal Year 2021 Results on Feb 24, 2022 Feb 03
Telix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 175.000002 million. Jan 28
Telix Pharmaceuticals Limited Doses 1St Patient in Prostact Prostate Cancer Therapy Program Jan 27
Telix Pharmaceuticals Limited and Atonco S.A.S. Announces That First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer Dec 21
Telix Pharmaceuticals Limited announces FDA Approves Prostate Cancer Imaging Product, Illuccix® Dec 20
Telix Pharmaceuticals Limited Announces Illuccix EU Regulatory Submission Progress Update Dec 11
Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil Dec 02
Telix Pharmaceuticals Limited Announces FDA Extends New Drug Application Review Period for Illuccix Sep 24
Telix Pharmaceuticals Limited Announces That the United States Food and Drug Administration (Fda) Has Accepted the Investigational New Drug Application Sep 15
Telix Pharmaceuticals Limited Announces That the Last Patient Has Been Imaged in Phase I Clinical Study of Telix's Investigational Prostate Cancer Imaging Product Tlx591-CDx in Collaboration with Kanazawa University Sep 09 Great Ormond Street Hospital Receives UK Research Ethics Approval to Commence A Phase II Academic Study of Telix’s Investigational Product, TLX66 (90Y-DTPA-Besilesomab) Rendimenti per gli azionisti TLPP.F US Biotechs US Mercato 7D -7.9% -1.9% -2.8% 1Y 123.1% -5.7% 24.1%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: TLPP.F ha superato il US Biotechs che ha restituito -5.7 % nell'ultimo anno.
Rendimento vs Mercato: TLPP.F ha superato il mercato US che ha restituito 24.1 % nell'ultimo anno.
Volatilità dei prezzi Is TLPP.F's price volatile compared to industry and market? TLPP.F volatility TLPP.F Average Weekly Movement 6.6% Biotechs Industry Average Movement 10.9% Market Average Movement 6.3% 10% most volatile stocks in US Market 18.0% 10% least volatile stocks in US Market 3.1%
Prezzo delle azioni stabile: TLPP.F non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di TLPP.F è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 2015 423 Chris Behrenbruch telixpharma.com
Telix Pharmaceuticals Limited, una società biofarmaceutica in fase commerciale, si concentra sullo sviluppo e la commercializzazione di radiofarmaci terapeutici e diagnostici per il cancro e le malattie rare in Australia, Belgio, Giappone, Svizzera e Stati Uniti. L'azienda offre Illuccix per il trattamento del cancro alla prostata e TLX66-CDx per il trattamento dell'osteomielite per immagini. I suoi prodotti candidati includono TLX591, un coniugato anticorpo-farmaco per il trattamento del cancro alla prostata; TLX250-CDx per il trattamento e la diagnosi del cancro renale; TLX101-CDx per il cancro al cervello (glioma); TLX66-CDx per il trattamento del condizionamento del midollo osseo; TLX300-CDx per il trattamento e la diagnosi del sarcoma dei tessuti molli; e TLX250 per il trattamento del carcinoma renale a cellule chiare.
Mostra di più Telix Pharmaceuticals Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Telix Pharmaceuticals con la sua capitalizzazione di mercato? TLPP.F statistiche fondamentali Capitalizzazione di mercato US$4.95b Guadagni(TTM ) US$30.51m Ricavi(TTM ) US$400.49m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) TLPP.F Conto economico (TTM ) Ricavi AU$645.68m Costo del fatturato AU$240.33m Profitto lordo AU$405.35m Altre spese AU$356.16m Guadagni AU$49.19m
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 0.15 Margine lordo 62.78% Margine di profitto netto 7.62% Rapporto debito/patrimonio netto 2.9%
Come si è comportato TLPP.F nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/02 12:05 Prezzo dell'azione a fine giornata 2025/01/02 00:00 Guadagni 2024/06/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Telix Pharmaceuticals Limited è coperta da 14 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Russell Wright Barclay Pearce Capital Pty Limited John Hester Bell Potter Andrew Paine CLSA
Mostra 11 altri analisti 
